Collaborative Pediatric Critical Care Research Network - Clinical Site

项目摘要/摘要-洛杉矶儿童医院 此申请表详细说明了洛杉矶儿童医院(CHLA)的资格、兴趣和承诺 成为儿科重症监护协作性研究网络(CPCCRN)的成员。 CHLA及其重症监护科的研究人员是儿科机械领域的国际专家 呼吸学、儿科急性呼吸窘迫综合征(PARDS)、信息学和数据科学。由Dr。 Khemani(Pi)和Newth博士(Co-I)，多学科CHLA呼吸研究小组及其成员 领导了PARDS的大型多中心观察性研究(Pardie Study，145个国际ICU)，并拥有 引领有关机械通风和PARDS的国际实践指南。这群人是 目前正在使用计算机化决策支持工具进行高度创新的单中心临床试验 靶向肺和横隔膜保护性通气在儿童ARDS中的应用 ICU后发病率的评估。这些独特的资格和专业知识将极大地丰富科学 CPCCRN内知识的严密性和广度。此外，CHLA的其他调查人员也是数据领域的先驱 科学、神经危重护理和实施科学，并将把这方面的专门知识带到中心。CHLA是 处于协作研究的前沿，多名教职员工在儿科急诊科担任领导职务 肺损伤和败血症调查员(PALISI)网络，儿科神经危重护理研究小组，以及 多中心数据协作，如VPS、VPICU和PICU数据协作。这一专业知识 强调我们的教员在研究网络中高度合作以实现共同目标的能力。它是 因此，CHLA在众多多中心临床试验中登记人数最高也就不足为奇了 儿科重症监护的观察性研究。为了进一步增强我们招聘大批员工的能力 将不同的患者纳入CPCCRN研究，我们将与儿童医院的辅助网站合作 奥兰治县(CHAC)。CHEC一直参与多中心合作研究，通过 Palisi网络已有10多年的历史，在临床试验中也取得了相当高的注册率。 通过我们的两个中心，我们可以确保在CPCCRN进行的临床试验(S)捕捉到独一无二的 南加州的种族、种族和社会经济多样性，其中包括50%的患者是 西班牙裔种族。这对于拟议的脓毒症免疫调节临床试验是必不可少的，因为 遗传、表观遗传、环境和社会经济因素可能对治疗和 结果。我们的网站有几名才华横溢的教职员工和初级调查人员，他们不仅将为 CPCCRN的成功，但可以进一步指导和发展成为未来的思想领袖和 临床/翻译研究人员通过CPCCRN。CHLA完全致力于成为一个积极参与和高度 CPCCRN的生产性成员，并执行申请中描述的临床试验。

PROJECT SUMMARY/ABSTRACT – Children’s Hospital Los Angeles This application details the qualifications, interest and commitment of Children’s Hospital Los Angeles (CHLA) to be a member of the Collaborative Pediatric Critical Care Research Network (CPCCRN). CHLA and its investigators in the division of critical care are international experts in pediatric mechanical ventilation, Pediatric Acute Respiratory Distress Syndrome (PARDS), informatics and data science. Led by Dr. Khemani (PI) and Dr. Newth (Co-I), the multi-disciplinary CHLA respiratory research group and its members have led large multi-center observational studies in PARDS (PARDIE study, 145 international ICUs), and have spearheaded international practice guidelines related to mechanical ventilation and PARDS. This group is currently running a highly innovative single center clinical trial using a computerized decision support tool targeting lung and diaphragm protective ventilation in pediatric ARDS, which includes comprehensive assessment of post-ICU morbidity. These unique qualifications and expertise will greatly enrich the scientific rigor and breadth of knowledge within the CPCCRN. In addition, other CHLA investigators are pioneers in data science, neurocritical care and implementation science, and will bring this expertise to the CPCCRN. CHLA is at the forefront of collaborative research, with several faculty holding leadership positions in the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network, the Pediatric Neurocritical Care Research Group, and multi-center data collaboratives such as VPS, VPICU, and the PICU Data Collaborative. This expertise underscores our faculty’s ability to be highly collaborative in a research network to achieve common goals. It is therefore not surprising that CHLA has been the highest enroller in a multitude of multi-center clinical trials and observational studies in pediatric critical care. To further enhance our ability to recruit a large number of diverse patients into the CPCCRN studies, we will partner with an ancillary site at Children’s Hospital of Orange County (CHOC). CHOC has been participating in multi-center collaborative research through the PALISI network for over 10 years and has also achieved remarkably high enrollment rates in clinical trials. Through our two centers, we can ensure that the clinical trial(s) conducted in the CPCCRN capture the unique ethnic, racial, and socio-economic diversity of Southern California which includes > 50% of patients being of Hispanic ethnicity. This is imperative for the proposed clinical trial on immune-modulation in sepsis, given the impact that genetic, epigenetic, environmental, and socio-economic factors may have on treatment and outcomes. Our site has several highly talented faculty and junior investigators who will not only contribute to the success of the CPCCRN but can be further mentored and developed into future thought leaders and clinical/translational researchers through the CPCCRN. CHLA is fully committed to be an engaged and highly productive member of the CPCCRN and execute the clinical trial described in the application.